American Society of Ketamine

Physicians, Psychotherapists & Practitioners

JOIN ASKP3

Who Is ASKP3 ?

The American Society of Ketamine Physicians, Psychotherapists, and Practitioners is a non-profit group of professionals dedicated to the safe clinical use of ketamine for mental health disorders and pain conditions.
Our mission and vision

0 +

Members

Active members of ASKP3 worldwide.

0 +

States and Countries

Locations of our active members globally.

ASKP3 Mission Statement:

Our mission is to further awareness and education regarding safe, effective and ethical therapeutic use of ketamine

ASKP3 Vision Statement:

Our vision is to advance the treatment of mental and physical health through the use of ketamine by:

1. Establishing scientific, ethical and transparent standards among practitioners;

2. Advancing the quality of care through the furthering of knowledge, the exchange of ideas, and research;

3. Fostering multidisciplinary collaboration to improve patient outcomes;

4. Educating the clinical communities about all aspects of this treatment modality;

5. Building awareness and understanding among the general population, legislators, regulators and payers;

6. Welcoming relationships that support the development of other psychedelic therapies;

ASKP3 is officially open for membership

Submit your application

All applications are subject to approval

ASKP3 is officially open for membership

JOIN ASKP3

2020-2021 American Society of Ketamine Physicians,
Psychotherapists & Practitioners Officers & Board Members

Sandhya Prashad, M.D.
Founding Member - President

Megan Oxley, M.D.
Founding Member-Vice President

Cindy Van Praag, M.D.
Board Member-Secretary

Robert Grant, M.D., M.P.H.
Board Member - Treasurer

Steven Mandel, M.D.
Founding Member - Board Member

Nykol Bailey Rice, CRNA
Board Member

Patrick Sullivan, D.O.
Board Member

Call For ASKP3 Patient Advocate Board Member

ASKP3 is currently accepting Patient Advocate Board Member Applications through October 24th.  Applications can be located at the link below.

 

Submissions are required by on October 24th. Please direct any questions to info@askp.org. We look forward to reading your application.

 

The ASKP3 patient advocate board position is a voluntary, non-paid position. The time commitment required of a board member consists of 1-2 board meetings per month, 1-2 sub-committee meetings per month as well as writing and/or research projects. Board members are also expected to attend our annual meeting in the fall and our in-person board retreat over a weekend in the spring. In summary, board members spend 6-10 hours a month on ASKP3 activities in addition to the two weekends of the year.  The patient advocate board position is a non-voting position on the board.

 

 

Application for ASKP­3 Patient Advocate Board Member Application

Basics of Administration

All of the providers in our group ascribe to the same basic tenets of safety when administering Ketamine for Non-Anesthetic Indications (KNAI).

1. ASKP3 serves as a forum to discuss the use of therapeutic ketamine for Non-Anesthetic Indications (KNAI).

2. We recognize that therapeutic ketamine is being administered by clinicians through different routes of delivery (IV, IM, IN, PO, etc.).

We recognize that therapeutic ketamine is being administered by clinicians through different routes of delivery (IV, IM, IN, PO, etc.). ASKP3 does not endorse any particular route of delivery however we feel it is important that the combination of delivery and dose do not cross over from KNAI to moderate sedation unless the provider and clinical setting are appropriate for that treatment.

3. Patients should be screened for and have been found to have a condition that is appropriate for ketamine treatment.

Patients should be screened for and have been found to have a condition that is appropriate for ketamine treatment – examples include Unipolar Major Depression, Bipolar Depression, PTSD, OCD, Fibromyalgia, CRPS and other forms of chronic pain.

4. A full history and physical including psychiatric disorders and substance abuse disorders should be completed in the patient’s chart.

A full history and physical including psychiatric disorders and substance abuse disorders should be completed in the patient’s chart. The patient’s medications and allergies should also be documented to reduce reasonable risk of medication interaction and side effects.

5. Given the off-label nature of ketamine use for these disorders, appropriate consent should be obtained.

Given the off-label nature of ketamine use for these disorders, appropriate consent should be obtained.

6. Practitioners should have their established protocol easily available to the public.

Practitioners should have their established protocol easily available to the public. The use of “secret formulations” and “proprietary blends” runs counter to the concept of evidence-based medicine.

7. The patient’s vital signs should be monitored during administration and return to pre-administration values before discharge from the clinic.

The patient’s vital signs should be monitored during administration and return to pre-administration values before discharge from the clinic.  An appropriately licensed and qualified medical provider should be present during the administration as well.

8. Patients receiving ketamine therapeutically should not be allowed to drive themselves home from their appointment, or for 12 hours after their infusion.

Patients receiving ketamine therapeutically should not be allowed to drive themselves home from their appointment, or for 12 hours after their infusion.

9. We do not support the use of medically unsupervised parenterally administered ketamine.

We do not support the use of medically unsupervised parenterally administered ketamine.

2020 ASKP3 Annual Meeting

Conference runs October 13th – 17th

Stay up to date with ASKP3